Introduction
Lung cancer ranks the first most common cancer and the first most frequent cause of cancer death in China. Meanwhile, the American Cancer Society lists lung cancer as the leading cause of cancer death in the United States (Winer et al., 2009) . Non-small cell lung cancer (NSCLC) accounts for around 84% of lung cancers (Detterbeck et al., 2009) . Despite the advance of surgical treatment, the 5-year survival of NSCLC has remained at a dismal 15% in the past three decades (Jemal et al., 2008) . It is therefore imperative to deepen the understanding of the molecular mechanism of NSCLC, and to find novel therapeutic strategies for this disease.
Notch signaling is one of the fundamental signaling pathways that enable cell-cell communication in multicellular organisms, regulating certain cellular response during embryonic and postnatal development (Artavanis-Tsakonas et al., 1999; Fortini, 2009 ). In mammals, there are four heterodimeric transmembrane receptors (Notch1-4), two Serrate-like (Jagged-1 and Jagged-2) and three delta-like (Dll1, Dll3 and Dll4) ligands. Notch activation occurs when the ligand engagement renders the notch intracellular domain to be cleaved from the cell membrane and translocate into the nucleus, where it combines with the CSL (CBF1/Su(H)/Lag-1) family of DNA-binding proteins to form a transcriptional active complex and activates the transcription of Notch-target genes such as HES1 and HEY1 (Deftos and Bevan, 2000; Collins et al., 2004; Kunnimalaiyaan and Chen, 2007) . It was reported that depletion of Notch interrupts lung development in mice (Collins et al., 2004) . Accumulating evidence has revealed the aberrant expression of Notch components including Notch1, Notch3 and HES1 in NSCLC. However, the role of Notch in lung cancer development remains elusive (Collins et al., 2004; Haruki et al., 2005; Chen et al., 2007) .
As an endothelium-specific Notch ligand, Dll4 expression is restricted to endothelial cells (ECs) during embryonic vascular development and angiogenesis of tumors (Mailhos et al., 2001; Yan and Plowman, 2007) . Blocking Dll4/Notch signaling impairs tumor growth, which might be due to the poor blood perfusion resulted from the non-functional branched vasculature (No-guera-Troise et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007) . The vast majority of these studies focused on the effect of Dll4/Notch interaction in tumor angiogenesis. However, it is largely unknown whether Dll4 of vascular ECs could regulate Notch signaling in tumor cells. In the present study, using a wellestablished cell coculture model (Nor et al., 2001; Zeng et al 2005) , we investigated the role of endothelial Dll4 in NSCLC growth and the underlying mechanism.
Results and discussion
Cell-to-cell contact is indispensable in ligand-mediated Notch activation, and it is not restricted to the same cell type (Deftos and Bevan, 2000; Collins et al., 2004) . Interaction of Jagged-1 or Dll4 with Notch receptors has been shown to promote head and neck squamous cell carcinomas angiogenesis or T-ALL (T-cell acute lymphoblastic leukemia) development (Zeng et al., 2005; Indraccolo et al., 2009) . However, little is known about Dll4/Notch signaling-mediated cross-talk between endothelial cell and lung carcinoma. In current study, we investigated the effect of Dll4 on NSCLC cell proliferation using recombinant human Dll4 protein (rhDll4). As shown in Figure 1a , the proliferation of A549 cells was significantly inhibited upon rhDll4 treatment. To explore the role of endothelial Dll4 in cross-talk between ECs and NSCLC cells, we established HUVEC (human umbilical vein endothelial cells)-stable transfectants over-expressing Dll4 (EC-Dll4) or small-hairpin RNA against Dll4 (EC-shDll4) as well as control cells (Supplementary Figure S1a) . In an in vitro assay, proliferation of NSCLC cells cocultured with EC-Dll4 was significantly inhibited compared with those cocultured with EC-EV. In contrast, stably silencing Dll4 in ECs by its specific shRNA remarkably increased the proliferation of NSCLC cells. (Figures 1b and c) . Apoptotic A549 cells were detected in this coculture system, but no significant differences among the three groups were observed (Supplementary Figure S1b) . These data suggest that endothelial Dll4 could mediate the proliferation of NSCLC cells.
To explore the role of endothelial Dll4 on lung cancer development in vivo, nude mice were injected subcutaneously with a mixed populations of human ECs and A549 cancer cells as previously described (Nor et al., 2001; Zeng et al., 2005) . As shown in Figures 2a-c, A549 cells mixed with EC-Dll4 developed smaller tumors than those mixed with EC-EV, whereas tumors induced by A549 cells mixed with EC-shDll4 exhibited larger size. A549 cells in xenograft of EC-Dll4 group showed limited growth, whereas the cells in EC-shDll4 group proliferated more rapidly compared with the control group, indicating the suppressive effect of endothelial Dll4 on the proliferation of cancer cells in vivo ( Figure 2d and Supplementary Figure S1c) . These results further confirmed that endothelial Dll4 could negatively regulate the development of NSCLC.
Aberrant expression of Notch in NSCLC has been illustrated in various studies (Collins et al., 2004; Haruki et al., 2005; Kunnimalaiyaan and Chen, 2007) . Notch3 was reported to be overexpressed in about 40% of NSCLC, and its chromosomal translocation has been detected in certain lung cancer tissue, suggesting that Notch3 could be an oncogene in NSCLC (Haruki et al., 2005) . Previous studies also documented that Notch1 was frequently expressed in lung cancer and correlated with the malignancy of NSCLC (Collins et al., 2004) . In contrast, recent studies have demonstrated reduced or even undetectable Notch1 expression in NSCLC, implying its tumor-suppressive role in NSCLC Konishi et al., 2007) . To explore the precise mechanism involved in the interaction between endothelial Dll4 and Notch receptors of NSCLC, we examined the mRNA levels of Notch in A549 cells cocultured with ECs. As shown in Figure 3a , silencing of Dll4 in ECs dramatically downregulated the expression of Notch1 in cocultured A549 cells, whereas levels of Notch2 and Notch3 were not influenced, implying that Notch1 but not Notch2 or Notch3 was involved in endothelial Dll4-mediated Notch activation in NSCLC cells. HES1 and HEY1 are the predominant target genes Figure 1 Endothelial Dll4 inhibited the proliferation of NSCLC cells. Human NSCLC-cell lines A549 and NCI-H460, human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM with 10% fetal bovine serum at 37 1C in a humidified 5% CO 2 incubator. HUVECs were transfected with plasmid carrying Dll4-encoding sequence, shRNA against Dll4 or vector control, respectively, using PEI (Invitrogen, Carlsbad, CA, USA) followed by 300 mg/ml G418 selection. Stable transfectants established were designated as HUVEC-Dll4 (EC-Dll4), HUVEC-shDll4 (EC-shDll4) or their control cells HUVEC-EV (EC-EV). Total RNA was extracted using TRIzol (Invitrogen). cDNA synthesis and realtime-PCR were performed as described previously (Wen et al., 2010) . Real-time PCR was performed using SYBR Green Premix Ex Taq II (TaKaRa, Bio Inc., Shiga, Japan) in an ABI 7300 thermal cycler (Applied Biosystems, Foster City, CA, USA). Primer sequences are listed in Supplementary Table S1 . Western blot was performed using an IRDye 800CW-conjugated antibody and LI-COR imaging system (LI-COR Biosciences, Superior Street, Lincoln, NE, USA). The antibodies used are listed in Supplementary  Table S2 . Recombinant human Dll4 (rhDll4) protein was purchased from R&D Systems. (a) A549 cells were seeded in 96-well plates (3 Â 10 3 cells/well in 0.1 ml 10% FBS DMEM) pre-incubated with 50 ml rhDll4 (1 mg/ml in PBS) or 0.1% BSA for 18-20 h at 4 1C as previously described (Williams et al., 2006) . Cell proliferation was measured using cell counting kit-8 (Dojindo Laboratories, Kumamoto, Japan) after 72 h, and the results were expressed as relative proliferation index (mean ± s.d.) as previously described (Wen et al., 2010) Figure S2a) . In further study, stable transfectant of A549 cells expressing shNotch1 was established (Supplementary Figure S2b) . As expected, suppressive effect of rhDll4 on cell proliferation was significantly impaired in A549 cells stably expressing ) were mixed with equal amount of EC-Dll4, EC-shDll4 or EC-EV, respectively, and implanted subcutaneously into nude mice as described previously (Nor et al., 2001; Zeng et al., 2005) . Tumor development was monitored by calculating tumor volume as described previously (Indraccolo et al., 2009) . Xenograft tumors were resected at the 21st day after inoculation and subjected to immunohistochemistry. Figure S2c ). It has been reported that cross-talk between Notch signaling and PI3K/Akt pathway could influence tumor progression (Kunnimalaiyaan and Chen, 2007; Meurette et al., 2009) . Notch1 activation was reported to suppress the expression of PTEN, a key molecule in PI3K/Akt pathway, in T-ALL and mesothelioma cell (Palomero Graziani et al., 2008) . There was also a report concerning the involvement of Notch1 in PTEN upregulation in human 293 cells (Whelan et al., 2007) . Considering PTEN has a critical and suppressive role in cancer cell growth and tumor development (Salmena et al., 2008; Yin and Shen, 2008) , we investigated whether Notch1 activation by endothelial Dll4 could influence PTEN expression in NSCLC. As shown in Figure 4a , expression of PTEN was much higher in A549 cells cocultured with EC-Dll4 than A549 cells cocultured with EC-EV. Additionally, there was no significant difference of Notch1 activation and PTEN expression in A549 cells treated with the culture medium of ECs (Supplementary Figure S3a) , which rules out the possibility that Dll4-mediated suppression of A549 cells was because of the soluble factors from ECs. Consistently, induction of N1ICD and PTEN was observed in A549 cells exposed to rhDll4 in parallel with the reduction of Akt phosphorylation as well as slight increase of PTEN phosphorylation (Figure 4b and Supplementary Figure S3b) . Overexpression of Notch1-ICD remarkably upregulated the expression of PTEN, and the interference of Notch1 dramatically downregulated PTEN expression (Supplementary Figure S3c) , which suggests the positive regulation of PTEN by Notch1. As shown in Figures 4c and d , increased level and nuclear translocation of Notch1ICD was observed in tumors with EC-Dll4, whereas it was decreased in tumors with EC-shDll4 compared with control tumors. More importantly, PTEN expression was upregulated in tumors with EC-Dll4 and downregulated in tumors with ECshDll4, which was concomitant with the activation of Notch1. These data suggest that PTEN is involved in Dll4/Notch1-mediated suppression of NSCLC.
In growing tumor, rapid proliferation of cancer cells renders local hypoxia, which induces vascular endothelial growth factor expression (Lobov et al., 2007) . Dll4 is usually upregulated by vascular endothelial growth factor in endothelial tip cells, which possess high Dll4 and low Notch (Patel et al., 2005; Hofmann and Luisa Iruela-Arispe, 2007; Benedito et al., 2009) . The enhanced Dll4 could activate Notch in the adjacent stalk cells, which exhibit high Notch and low Dll4 (Hofmann and Luisa Iruela-Arispe, 2007; Phng and Gerhardt, 2009 ). Notch activation sequentially improves the function of microvessels, and lack of Dll4 in stalk cells also permits the proliferation of neighboring tumor cells (Li et al., 2007; Phng and Gerhardt, 2009) . Antiangiogenic therapy for cancer emerged in early 1970s, marked with the publication of the Folkman's hypothesis (Folkman, 1971) . Dll4/Notch cascade has been considered as a pivotal signaling pathway in tumor angiogenesis. It has been documented that blockage of cancerous Dll4/endothelial Notch signaling favors the development of nonfunctional branched vasculature, thus leading to poor blood perfusion of numerous cancers (NogueraTroise et al., 2006; and Ridgway et al., 2006) . Segarra M et al. proposed that the blockage of Dll4/Notch signaling by neutralizing antibody remarkably promoted the angiogenesis of Burkitt's lymphoma (Segarra et al., 2008) . Yan M et al. recently reported that persistent Dll4 blockage in ECs led to the occurrence of vascular neoplasm (Yan et al., 2010) . Intriguingly, despite the regulatory role in angiogenesis, endothelial Dll4 was demonstrated to interact with Notch3 of neighboring tumor cells, and facilitate T-ALL and colorectal cancer progression (Indraccolo et al., 2009) . In this report, we have elucidated that endothelial Dll4 could inhibit NSCLC growth by, at least partially, the Notch1/ PTEN-dependent pathway. These results not only advance our understanding on the cross-talk between vascular ECs and cancer cells, but also provide a novel strategy for lung cancer therapy.
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